Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • NSI-189/MDD Neurogenic Biomarker Data Presented 11.17.14

      Depression blood-based biomarker analysis presented at CNS Summit shows NSI-189 rapidly and persistently efficacious. More

    • “The Moments You Live For” 11.12.14

      Dr. Eva Feldman’s clinical and pre-clinical work underway with Neuralstem’s neural stem cell platform technology to treat neurodegenerative disorders is featured in The Detroit News. More

    • NSI-566/ALS Study Shows Long-term Cell Survival and Differentiation 11.10.14

      Scientific data shows cells survive up to 2.5 years and suggests continued immunosuppression not required for transplanted cell survival. More

    • First Data on Alzheimer’s Disease
      Cell Therapy Presented 10.23.14

      Neuralstem’s NSI-532.IGF cells rescued spatial learning and memory deficits in animal data presented by University of Michigan at the Congress of Neurological Surgeons Annual Meeting. More

    • Neuralstem’s CEO BioWorld Interview on NSI-566/cSCI 10.10.14

      Richard Garr discusses the promise, similarities and differences of NSI-566 cell therapy for the second FDA-approved U.S. trial indication: chronic spinal cord injury, now underway in Phase I. More

    • First Spinal Cord Injury Phase I Patient Treated at UCSD 10.9.14

      Second indication in U.S. using NSI-566 stem cells adds structural repair mechanism of action, “bridging the circuitry gap,” to neuroprotective factor expression demonstrated in ALS trials. More

    • NSI-566/ALS Phase I Three-year Data, Ongoing Trial Called “Groundbreaking Progress” 9.22.14

      Emory site investigator, Dr. Jonathan Glass, presented data showing significant slowed disease progression or improvement three years’ post-treatment of lumbar/cervical final cohort in lower dose Phase I trial. More

    • Neuralstem “Takes the Real Ice Bucket Challenge” 9.2.14

      MarketWatch’s Michael Brush looks to the potential of Neuralstem’s NSI-566 for ALS treatments on the heels of the $100 million-plus raised in the ALSA Ice Bucket Challenge. More

    • UCSD Launches FDA-approved NSI-566/cSCI Phase I Trial 8.12.14

      Researchers put out the call for cSCI patients with T7-T12 thoracic spinal cord injuries that occurred between 1-2 years ago. More

    • Dr. Eva Feldman to determine how NSI-566 “slows down the progression” of ALS in trial patients 8.1.14

      NSI-566/ALS’s principal investigator also shares insights into Neuralstem’s upcoming ALS registration trial, and just-concluded animal research on Alzheimer’s disease. More

    • The Wall Street Journal Reports on Social Media During Trials 7.30.14

      CEO Richard Garr is interviewed in this front-page story that examines patient-directed social media’s impact on blinded clinical trials. More

    • EEG Findings Show NSI-189 Measurable Impact on Hippocampal Region in
      Phase I Trial 6.19.14

      Researchers report that neurogenic NSI-189 increased high-frequency brain wave activity in the left temporal region, where the hippocampus is located, in NSI-189/MDD select data to be presented at CINP World Congress. More

    • Neurogenic NSI-189 Phase I Data Heralds First-time Depression Field Findings 6.18.14

      Mass Gen/Harvard’s Dr. Marlene Freeman presents data, showing significant effect size in antidepressant activity and cognitive function improvement spanning NSI-189/MDD trial duration, at ASCP Annual Meeting. More

    • Advance Posting of NSI-189/MDD Speaker Abstract 5.23.14

      Study author, Marlene Freeman, MD, of Mass General and Harvard Medical School, to present neurogenic small molecule NSI-189 Phase Ib MDD data at ASCP annual meeting in June. More

    • BioPharm Insight CEO Interview on NSI-189 Strategy 5.8.14

      Richard Garr discusses corporate approach for commercialization, and Phase II/MDD plans, of its lead neurogenic small molecule compound. More

    • Former Genzyme EVP Joins Board 5.8.14

      Sandford Drexel Smith brings vast product launch and global commercialization expertise to Neuralstem’s board, directed international division of world’s most successful rare disease company. More

    • CEO Richard Garr Q&A on NSI-189/MDD 5.1.14

      Larry Smith’s expansive report provides new insights and detailed background on Neuralstem’s novel neurogenic small molecule program, in advance of upcoming NSI-189/MDD Phase I data presentation. More

    • CNN’s Miriam Falco Reports on NSI-566 Promise for Spinal Cord Injuries 4.16.14

      Neuralstem’s Karl Johe, PhD and Richard Garr give insights on the ability of NSI-566 to "actually build new circuitry” and “jump the gap with the new circuitry we've built.” More

    • NSI-566/Spinal Cord Injury Trial Gains UCSD IRB Approval 4.16.14

      FDA-approved, one-year Phase I cSCI trial to use same cells and surgical procedure as Neuralstem’s ongoing ALS Phase II trials. More

    • NSI-566/Stroke Study Published 3.28.14

      Science journal, PLOS ONE, publishes USF rat study showing significant improvement post-stroke and validates cell survival and functionality in the brain. More

    • NSI-566/ALS Final Phase I Data 3.17.14

      Annals of Neurology first to report outcomes of cervical and dual-targeted NSI-566 transplantations, which show Neuralstem’s cells replace lost cells, provide neurotrophic support, and improve the diseased microenvironment. More

    • NSI-566/Stroke: “A crucial step forward for the field at large…” 2.5.14

      “Optimizing cell therapy treatment for CNS indications will require delivering cells to the brain, as well as to the spinal cord.” - Neuralstem's CSO, Dr. Johe, quoted in a BioWorld article. More

    • Catherine Sohn, Pharm.D., Joins
      Board of Directors 1.14.14

      Dr. Sohn brings extensive commercialization expertise to Neuralstem’s Board, having served as SVP of Business Development & Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline during her 28-year tenure there. More

    • First NSI-566/Ischemic Stroke
      Phase I/II Patient Treated 1.13.14

      December 2013 marked the first transplantation of NSI-566 directly into a patient’s brain, at BaYi Brain Hospital in Beijing, where the Neuralstem China Phase I/II ischemic stroke trial is underway. More

    • BioWorld Today Feature Previews
      2014 Clinical Trials 1.6.14

      Randy Osborne talks to Richard Garr about NSI-566/ALS Phase II, NSI-189/MDD Phase II filing, and FDA-approved NSI-566/cSCI Phase I. More

    • FORBES Gives “A Closer Look at Neuralstem’s ALS Treatment” 11.21.13

      John Farrell interviews Richard Garr in this expansive feature that explores the business and science sides of Neuralstem’s NSI-566. More

    • FOX Medical Team In-depth Feature: The Promise of Hope 11.5.13

      Beth Galvin reports on Neuralstem’s first NSI-566/ALS Phase II patient two months post-treatment of ten injections of a total of two million cells at Emory University. View Segment

    • "A Better Pill To Swallow" 10.23.13

      David Frey’s feature story on depression and the potential transformative promise of neurogenic NSI-189 is brimming with insights on the company’s founders and what CSO Dr. Johe calls “a potential ‘vitamin for the brain’ to slow down or counter that aging process in our mental capacity.” More

    • Emory’s Drs. Glass and Boulis Interviewed about NSI-566/ALS
      Phase II 10.3.13

      “The Phase II trial will help us better understand if more injections with more cells can improve conditions for the patient in a safe manner,” says Dr. Boulis, who is teaching other neurosurgeons the proper procedures for implanting NSI-566. More

    • NSI-566 Reverses Cognitive Defect in Brain-Irradiated Animals 8.1.13

      Transplanted rats improved hippocampal spatial memory as well as intact amygdala function, in model similar to clinical irradiation intervention given to treat brain cancer patients, in published paper by UC Irvine researchers. More

    • NSI-566 Induce Improvement in Acute Spinal Cord Injury Rats Three Days Post-Injury 5.28.13

      Latest published research from UCSD's Dr. Marsala demonstrates that intraspinal grafting of NSI-566 cells during the acute SCI phase could represent an effective treatment that ameliorates post-injury motor and sensory deficits. UCSD cited as a center in Neuralstem's upcoming 2013 cSCI clinical trial. More